Publications by authors named "A D Heini"
Introduction: The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are increasingly emerging.
Case Presentation: We report the case of a patient developing acute erythroid leukemia with biallelic inactivation occurring 26 months after CAR-T therapy with brexucabtagene autoleucel (brexu-cel) for r/r mantle cell lymphoma.
Introduction: The growing body of evidence around sexual and gender dimorphism in medicine, particularly in oncology, has highlighted differences in treatment response, outcomes, and side effects between males and females. Differences in drug metabolism, distribution, and elimination, influenced by factors like body composition and enzyme expression, contribute to these variations.
Methods: We retrospectively analyzed data of 112 multiple myeloma (MM) patients treated with first-line high-dose chemotherapy (HDCT) with treosulfan and melphalan (TreoMel) followed by autologous stem cell transplantation (ASCT) at a single academic center between January 2020 and August 2022.
Nutrition has powerful impacts on our health and longevity. One of the mechanisms by which nutrition might influence our health is by inducing epigenetic modifications, modulating the molecular mechanisms that regulate aging. Observational studies have provided evidence of a relationship between nutrition and differences in DNA methylation.
View Article and Find Full Text PDFArticle Synopsis
- Bispecific antibodies, like talquetamab, have improved treatment options for multiple myeloma by redirecting T cells to target specific cancer cells.
- Talquetamab targets GPRC5D, leading to skin toxicity, which poses challenges for patient management.
- A case study revealed that a patient experienced severe skin toxicity from talquetamab following a stem cell treatment, highlighting the need for personalized care in using novel immunotherapies alongside traditional treatments.
Article Synopsis
- Personalized treatment options for patients with diffuse large B-cell lymphoma (DLBCL) are being developed, with a focus on specific treatments for different patient groups.
- Caracciolo et al. investigate UMG1, a specific part of the CD43 protein, as a potential therapeutic target and find encouraging results with an Anti-UMG1-antibody in preclinical studies.
- The study highlights the use of a bispecific T-cell engager (BTCE) that redirects T-cell activity to effectively target DLBCL.